Astria Therapeutics, Inc. (ATXS)

10.89 +0.08 (+0.74%) At close: 04:00PM EDT

Astria Therapeutics, Inc.

75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971
https://www.astriatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 59

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Jill C. Milne Ph.D.	Co-Founder, CEO, President & Director	928.52k	N/A	1968
Mr. Benjamin S. Harshbarger J.D.	Chief Legal Officer	621.91k	N/A	1969
Mr. Noah C. Clauser CPA	CFO & Treasurer	508.79k	N/A	1974
Ms. Keri McGrail	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Andrea L. Matthews	Chief Business Officer	N/A	N/A	N/A
Mr. Andrew A. Komjathy	Chief Commercial Officer	N/A	N/A	1964
Dr. Christopher J. Morabito M.D.	Chief Medical Officer	N/A	N/A	1971
Mr. John Ruesch	Senior Vice President of Pharmaceutical Sciences & Technical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Corporate governance

Astria Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.